Early View

Original research article

Validation of the HULL Score clinical prediction rule (CPR) for unsuspected pulmonary embolism in ambulatory cancer patients

Farzana Haque, Jessamine Ryde, Laura Broughton, Chao Huang, Sifut Sethi, Andrew Stephens, Annet Pillai, Shagufta Mirza, Victoria Brown, Ged Avery, Georgios Bozas, Anthony Maraveyas

Title

Validation of the HULL Score clinical prediction rule (CPR) for unsuspected pulmonary embolism in ambulatory cancer patients

Author name and affiliation

Farzana Haque[a,b], Jessamine Ryde[a], Laura Broughton[b], Chao Huang[b], Sifut Sethi[a], Andrew Stephens[a], Annet Pillai[a], Shagufta Mirza[a], Victoria Brown[a], Ged Avery[a.b], Georgios Bozas[a], Anthony Maraveyas[a,b]

a Hull University Teaching Hospital NHS Trust

  Castle Hill Hospital

  Castle Road, Hull

  HU16 5JQ

  United Kingdom 0

b Hull York Medical School

  Allam Medical Building

  University of Hull, Hull

  HU6 7RX

  United Kingdom

Corresponding author

Dr. Farzana Haque

The Hull York Medical School, Faculty of Health Sciences

Castle Hill Hospital

Castle Road, Hull HU16 5JQ,

United Kingdom

Phone: +44 1482 875875

E-mail: Farzana.haque4@nhs.net

Abstract

BACKGROUND: Clinical prediction rules (CPRs) developed to predict adverse outcomes of suspected pulmonary embolism (PE) and facilitate outpatient management have limitations in discriminating outcomes for ambulatory cancer patients with unsuspected PE (UPE). The HULL Score CPR uses a 5-point scoring system incorporating performance status (PS) and self-reported new or recently evolving symptoms at UPE diagnosis. It stratifies patients into low, intermediate and high risk for proximate mortality.

AIM: This study aimed validation of the HULL Score CPR in ambulatory cancer patients with UPE.

PATIENTS AND METHODS: 282 consecutive patients managed under the UPE-acute oncology service in Hull University Teaching Hospitals NHS Trust were included from January 2015 to March 2020. The primary endpoint was all-cause mortality, and outcome measures were proximate mortality for the three risk categories of the Hull Score CPR.

RESULTS: 30-day, 90-day and 180-day mortality for the whole cohort was 3.4% (n=7), 21.1% (n=43) and 39.2% (n= 80), respectively. The HULL Score CPR stratified patients into low 35.5% (100), intermediate 33.7% (95) and high 28.7% (81) risk groups. Correlation of the risk categories with 30-day, 90-day, 180-day mortality and OS was consistent with the derivation cohort (area under the curve [AUC] 0.717 [95% CI 0.522, 0.912], AUC 0.772 [95% CI 0.707, 0.838], AUC 0.751 [95% CI 0.692, 0.809], AUC 0.749 [95% CI 0.686, 0.811], respectively).

CONCLUSION: This study validates the capacity of the HULL Score CPR to stratify proximate mortality risk in ambulatory cancer patients with UPE. The score uses immediately available clinical parameters and is easy to integrate into an acute outpatient oncology setting.

Abbreviations

AUC – Area Under the Curve, CI – Confidence Interval, CPR – Clinical Prediction Rule, CT – Computed Tomography, DVT – Deep Vein Thrombosis, ECOG – Eastern Co-operative Oncology Group, IQR – Interquartile Range, MB – Major Bleeding, PE – Pulmonary Embolism, UPE – Unsuspected Pulmonary Embolism, ROC – Receiver Operator Characteristics, S-UPE – Symptomatic Unexpected Pulmonary Embolism, rVTE – Recurrent Venous Thromboembolism, VTE – Venous Thromboembolism.

Introduction

Cancer patients are at a higher risk of being diagnosed with unsuspected pulmonary embolism (UPE) than the general population. UPE is a pulmonary embolism diagnosed on a computed tomography (CT) scan performed for reasons other than a clinical suspicion of pulmonary embolism. The imaging, therefore, has been performed with a non-angiography protocol. The widespread use of whole-body multi-slice computed tomography (WBCT) in cancer diagnosis, assessment of treatment response, and surveillance has resulted in an apparent increase in the incidence of UPE (1-3). A meta-analysis including over 10,000 patients reported a weighted mean prevalence of UPE in cancer patients of 3.1% compared to 2.5% in non-cancer patients (4) while, in a recent review, the incidence varies from less than 1% to 15% or higher (5), representing half of the pulmonary embolism (PE) currently diagnosed in oncology (5, 6). UPE is also increasingly described in cancer associated thrombosis (CAT) randomised controlled trials (RCTs) (7).

Unsuspected Pes share similar risk factors and embolic burden with suspected Pes (8). Likewise, consequences of UPE do not differ significantly from suspected PE with a similar prognosis to symptomatic events, comparable 1-year recurrence risks, risks of major bleeding complications and overall survival (OS) and mortality rates (9-11). Therefore, international clinical guidelines recommend treating all patients with UPE with the same long-term (at least 3 to 6 months) anticoagulation as for suspected PE (12).

Several clinical prediction rules (CPRs) for risk stratification of PE diagnosed upon suspicion exist (13-16). These are designed to facilitate outpatient management but have limitations in discriminating outcomes for ambulatory cancer patients with UPE (17). There are also limitations with cancer-specific PE-CPRs when it comes to risk stratifying ambulatory cancer patients with UPE (18-20).

From the study of a cohort of 234 ambulatory cancer patients with UPE, we found that consistent predictors of proximate mortality were the patients' reports of new symptoms or worsening of pre-existing symptoms, along with ECOG performance status (PS) impairment at the time of UPE diagnosis. Using these parameters, a clinical prognostic score (the HULL Score CPR) predicting proximate mortality was derived (17). The validity of using symptoms and PS in this setting was recently reaffirmed in an external dataset, and the HULL Score CPR was validated (21).

This study aimed to provide a follow-on validation of the HULL Score CPR in ambulatory cancer patients with UPE managed at Hull University Teaching Hospitals NHS Trust.

Patients and methods

In the Queen's Centre for Oncology and Haematology, Hull University Teaching Hospitals (HUTH) NHS Trust, all patients with UPE are managed uniformly under a nurse-led 'Unsuspected PE pathway.' This is a dedicated referral and treatment pathway for oncology patients with UPE found on routine CT scans (22). These patients are risk-stratified by the HULL Score CPR (17), that stratifies patients into risk categories for proximate mortality (30, 90 and 180-days). It utilises a 5-point scoring system (HULL Score [HS]) incorporating Eastern Cooperative Oncology Group (ECOG) performance status (PS) and self-reported new or recently evolving symptoms at UPE diagnosis. The presence of new or worsening symptoms is weighted 1 point, ECOG 1 or 2 is weighted 2 points, and ECOG 3 or 4 is weighted 3 points. Cancer patients with UPE are categorised into the low-risk group if they score 0, intermediate-risk group if the score is 1 or 2 and high-risk group if the score is 3 or 4.

Patients

A prospective cohort of ambulatory cancer patients with UPE was managed between January 2015 to March 2020. Active cancer was defined as cancer present or receiving treatment (i.e., adjuvant treatment) or have received treatment for cancer within the past six months.

Outcome measures

The objective of this study was to validate the potential of HULL Score CPR to risk stratify the patient groups for proximate mortality in a follow-on cohort of patients from the same centre. Patients were followed until death or the end of follow-up, whichever occurred first. The primary endpoint was all-cause mortality by Hull Score CPR risk categories. Outcome measures were death within 30 days, 90 days and 180 days of presentation with UPE and in the overall study period. The HULL Score CPR was evaluated by individual category level for 30-days, 90-days, and 180-day mortality and overall survival, and the number of outcome events was reported by HULL Score CPR categories.

Data collection

Extensive demographic, clinical, laboratory and patient-reported outcome tools were collected at baseline presentation to the department as previously described (17). This data was stored in the Hull 'UPE database' in the oncology information system (OIS-ARIA). Outcome data for this study were collected from the electronic medical record system Lorenzo and IMPAX. The database was closed on September 30, 2020 (Audit no 2013.287). All information entered in the electronic database and clinical outcome was adjudicated by cancer and VTE multidisciplinary team members in the HUTH NHS Trust. The UPE events were not independently blindly adjudicated.

Analysis – Statistical consideration

Descriptive statistics were used to analyse patient characteristics. Survival was calculated from the date of PE diagnosis.

Survival analyses were performed by the Kaplan Meier with the log-rank test to assess the predictive ability of HULL CPR for proximate (30-day, 90-day and 180-day) mortality. The hazard ratios were calculated by Cox proportional hazards model to evaluate the association of proximate mortality with the prognostic risk group. Receiver Operator Characteristics (ROC) analysis was used to determine the discriminatory performance of HULL Score CPR. A probability level of 5% was used as the cut-off for statistical significance in all analyses. All analyses were performed with SPSS v25, IBM Corp ™ and STATA v17.0.

Results and discussion

The HULL Score CPR was developed from a prospectively collected UPE cohort (derivation cohort) of 234 consecutive cancer patients from a single center referred to a standardised diagnostic and management outpatient pathway from 2010 to 2014 (17, 22).

The present study analysed a prospective cohort of 282 patients in a single centre database (registry) from the same clinical setting as the derivation cohort. This cohort included consecutive ambulatory cancer patients with UPE from 2015 to 2020. As a validation study for the HULL Score CPR, our target was to have a sample size similar to the original one. We successfully recruited 282 for this validation cohort and this sample size provides sufficient data for the proposed analyses. There was no overlap of patients between the validation cohort and the derivation cohort or the international UPE registry.

The median Age was 69 years (Range 36-91), and 57.8% were male. The Median follow-up duration was 11.6 months (IQR 4.9, 21.4). At the time of database closure, 78 patients were alive.

Table 1 lists a description of baseline characteristics of the validation cohorts.

The most common cancer types were colorectal (17.7%), lung (10.3%) and breast cancer (9.2%). 72% of patients had metastatic cancer. UPE was confined to the sub-segmental arteries for 14.9% of patients. New symptoms or worsening symptoms were reported by 41.5% of patients.

The PS of patients in the derivation and validation cohorts was comparable. In the validation cohort, 47.2% had an ECOG PS of 0, and 44.7% had an ECOG PS of 1-2 (45% and 43% in the derivation cohort, respectively). Only 6% had ECOG PS of 3-4 (10% in the derivation cohort). These were consistent with an ambulatory outpatient cohort (91.9% with an ECOG-PS 0-2), and indeed 96.1% of patients were managed as outpatients for UPE in the validation cohort.

The HULL Score CPR stratified the validation cohort into low 100 (35.5%), intermediate 95 (33.7%) and high 81 (28.7%) risk groups for proximate mortality. 30, 90 and 180-day mortality for the whole cohort was 2.5% (n=7), 15.2% (n=43) and 28.4% (n= 80), respectively.

Figure 1b compares the 30, 90 and 180-day mortality by HULL Score CPR in derivation and validation cohorts. 30-day mortality was 0% and 1% in the low-risk, 0.9% and 1.1% in intermediate-risk, and 9% and 6.2% in the high-risk category for the derivation and validation cohort, respectively. Likewise, 90-day and 180-day mortality in the validation cohort demonstrated similar frequencies as reported in the derivation cohort. Higher mortality is observed in the intermediate and high-risk categories compared to the low-risk category, which is consistent with the derivation cohort. For example, 180-day mortality in the validation cohort in the high-risk category was 49.4% (55.2% in the derivation cohort), whereas, in the low-risk category, it was 4% (4.4% in the derivation cohort).

Similarly, the Kaplan Meier survival curves (Figure 1a) illustrate the statistically significant differences in survival in the first 12 months of follow-up for each category of HULL Score CPR in the derivation and validation cohort. The median OS for the entire validation cohort was 13 months and 12.6 months for the derivation cohort. Median OS in the validation

cohort was 30.2 (16.4, 44), 10 (6.4, 13.7) and 6.1 (2.9, 9.3) months for low, intermediate and high-risk category (*p<0.001)*; this was comparable to the derivation cohort (low-risk 32 (8.1, 55.9), intermediate-risk 12.6 (8.3, 16.9) and high-risk 5.5 (3.9, 7.2) months, respectively, *p<0.001*).

The cumulative hazard function for each prognostic category over time is presented in Table 2. In the high-risk category, the hazard of 30-day mortality was 6.3 times that of the low-risk category, 90-day mortality was 39.5 times, and 180-day mortality was 17.6 times (Table 2).

Correlation of the risk categories with 30-day, 90-day, 180-day mortality and OS was consistent with the derivation cohort (area under curve [AUC] 0.717 for 30-day [95% CI 0.522, 0.912*, p= 0.05*], AUC 0.772 for 90-day [95% CI 0.707, 0.838, *p <0.001*], AUC 0.751 for 180-day [95% CI 0.692, 0.809, *p <0.001*] and AUC 0.749 for OS [95% CI 0.686, 0.811, *p <0.001*], respectively), as shown in Figure 2.

UPE has become a frequent presentation, and advances in cancer treatment have resulted in more patients receiving care in an out-patient setting and multiple WBCT assessment scans. A validated, easy-to-use CPR would provide safe outpatient management, addressing the detrimental implications on quality of life and healthcare costs from unnecessary hospital admissions (22).

Many CPRs for PE have been developed to assess the suitability of outpatient management in the general population from the conventional symptomatic PE patients (23). However, the generic CPRs such as the Pulmonary Embolism Severity Index (PESI) or simplified PESI are not helpful for risk stratification of cancer-related UPE, especially for 30-day, 90-day and 180-day mortality in ambulatory cancer patients (17). Furthermore, scoring systems like the Computerised Registry of Patients with Venous Thromboembolism (RIETE) (18) or POMPE-C (19) developed from cancer patient cohorts with suspected PE have a limited role in discriminating between the low and high-risk groups for proximate mortality in ambulatory cancer patients with UPE.

The EPIPHANY index (20) has been developed from a mixed cohort of cancer patients with suspected and unsuspected PE (UPE) and validated externally in cancer patients. Though the EPIPHANY index predicts mortality, it does so based on very high mortality in the UPE cohort, suggesting that many of these patients were not ambulatory (21). The variation in

the characteristics of the EPIPHANY and HULL Score CPR cohorts is exemplified by the observed differences in the mortality (2-fold) of the symptomatic-UPE of EPIPHANY cohort compared to the sickest patients of the HULL Score CPR derivation and validation cohorts (HS 3,4). 30-day mortality were 9% and 6.2% in the high-risk group of the derivation and validation cohort, respectively, whereas it was 20% for the S-UPE of the EPIPHANY cohort. Likewise, 90-day mortality is significantly higher in the S-UPE EPIPHANY patients. This suggests that unwell inpatients with UPE were enrolled in the EPIPHANY study.

The prognostic value of new respiratory symptoms and PS status in ambulatory cancer patients with UPE was studied in the UPE registry, an international, prospective, observational cohort study, and the discriminatory value of the HULL Score CPR was confirmed (21). The most consistent predictors of mortality were patient-reported respiratory symptoms within 14-days before and ECOG-PS at the time of UPE. When applied to the HULL Score CPR, it produced consistent results with the derivation cohort of HULL Score CPR. Consistent correlation was found with 30-day, 90-day, 180-day mortality and OS (AUC = 0.70 [95% CI 0.63, 077], AUC = 0.65 [95% CI 0.60, 070], AUC = 0.64 [95% CI 0.59, 068] and AUC = 0.61 [95% CI 0.57, 0.65], respectively).

A recent post hoc analysis of the Hokusai-VTE cancer study also showed the importance of ECOG PS in predicting VTE-related outcomes, including recurrent VTE, major bleeding, and all-cause mortality (24). This may guide decision-making regarding anticoagulation during follow-up in patients with cancer-associated PE.

Our study has some limitations. Firstly, the long period over which cases were collected may have resulted in some differences in the baseline demographic traits of the two tandem derivation (Table 2 supplementary material) and validation cohorts Table 1. We highlight the reduced frequency of metastatic disease, the greater use of systemic anticancer treatment, including biologicals such as tyrosine kinase inhibitors and immunotherapy and the reduced frequency of some cancers for which thromboprophylaxis is becoming common (e.g., pancreatic ductal adenocarcinoma and gastro oesophageal cancer). Nevertheless, the very similar median and overall OS for the two cohorts suggests that these are well matched for this analysis.

It is also notable that the external validation study happened before the follow-on validation cohort could be collected. This was due to the faster accrual rate of a multicentre study and,

to the best of our knowledge, the absence of other cohorts with ambulatory cancer patients and UPE that have prospectively collected the relevant data.

Strengths of our study include the prospective design from the same clinical setting with uniform management protocol and a large study group. To avoid selection bias, we recruited consecutive patients from January 2015 to March 2020 to form this cohort. Further potential ways of improving HULL Score CPR are being investigated, such as considering the granularity of the 'symptoms' and including other biochemical parameters at UPE diagnosis.

This study validates the capacity of the HULL Score CPR to stratify proximate mortality risk in ambulatory cancer patients with UPE. It is composed of practical clinical parameters easy to obtain and use in an acute oncology setting and can guide appropriate decision-making in these patients.

Data statement

Data are available from the corresponding author on demand, at the discretion of the Hull University Teaching Hospitals NHS Trust Governance bodies, who are the legal guardians.

Ethics approval and consent to participate

This study was conducted under the UK Health Research Authority regulations as an Audit / Quality improvement project (QIP), not requiring Ethics Approval. This is an anonymised cohort collected as part of an audit process. Patient consent for anonymised data collection for audit purposes is not required. Regulatory compliance [as per the Data Protection Act (1998), the Caldicott principles (1997) and the NHS Confidentiality code of practice (2003)] was overseen by the Hull University Teaching Hospitals NHS Trust Governance bodies. Audit registration No. 2013.287.

Consent for publication

Not applicable. No individually identifiable data are presented in this work.

References

1.	Sebastian AJ, Paddon AJ. Clinically unsuspected pulmonary embolism—an important secondary finding in oncology CT. Clin Radiol. 2006;61(1):81-5.

2.	Khorana AA, O'Connell C, Agnelli G, Liebman HA, Lee AYY, Subcommittee on H, et al. Incidental venous thromboembolism in oncology patients. Journal of thrombosis and haemostasis : JTH. 2012;10(12):2602-4.

3.	Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol. 2007;189(1):162-70.

4.	Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, et al. Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis. Thrombosis Research. 2010;125(6):518-22.

5.	Di Nisio M, Carrier M. Incidental venous thromboembolism: is anticoagulation indicated? Hematology Am Soc Hematol Educ Program. 2017;2017(1):121-7.

6.	van Es N, Bleker SM, Di Nisio M. Cancer-associated unsuspected pulmonary embolism. Thrombosis Research. 2014;133:S172-S8.

7.	Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). Journal of Clinical Oncology. 2018;36(20):2017-23.

8.	van der Hulle T, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. Journal of thrombosis and haemostasis : JTH. 2016;14(1):105-13.

9.	Qdaisat A, Kamal M, Al-Breiki A, Goswami B, Wu CC, Zhou S, et al. Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients. Blood advances. 2020;4(8):1606-14.

10.	den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of Recurrent Venous Thromboembolism and Mortality in Patients With Cancer Incidentally Diagnosed With Pulmonary Embolism: A Comparison With Symptomatic Patients. Journal of Clinical Oncology. 2011;29(17):2405-9.

11.	Font C, Farrús B, Vidal L, Caralt TM, Visa L, Mellado B, et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Annals of Oncology. 2011;22(9):2101-6.

12.	Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 2019;38(5):496-520.

13.	Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172(8):1041-6.

14.	Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. A Prediction Rule to Identify Low-Risk Patients With Pulmonary Embolism. Archives of Internal Medicine. 2006;166(2):169-75.

15.	Righini M, Roy P-M, Meyer G, Verschuren F, Aujesky D, Le Gal G. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism. Journal of Thrombosis and Haemostasis. 2011;9(10):2115-7.

16.   Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, et al. Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism. Archives of Internal Medicine. 2010;170(15):1383-9.

17.   Bozas G, Jeffery N, Ramanujam-Venkatachala D, Avery G, Stephens A, Moss H, et al. Prognostic assessment for patients with cancer and incidental pulmonary embolism. Thrombosis Journal. 2018;16(1):8.

18.   den Exter PL, Gómez V, Jiménez D, Trujillo-Santos J, Muriel A, Huisman MV, et al. Registro Informatizado de la Enfermedad TromboEmbolica I. A Clinical Prognostic Model for the Identification of Low-Risk Patients With Acute Symptomatic Pulmonary Embolism and Active Cancer. CHEST. 2013;143(1):138-45.

19.   Kline JA, Roy PM, Than MP, Hernandez J, Courtney DM, Jones AE, et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C tool. Thromb Res. 2012;129(5):e194-9.

20.   Carmona-Bayonas A, Jiménez-Fonseca P, Font C, Fenoy F, Otero R, Beato C, et al. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Br J Cancer. 2017;116(8):994-1001.

21.   Maraveyas A, Kraaijpoel N, Bozas G, Huang C, Mahé I, Bertoletti L, et al. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. Journal of Thrombosis and Haemostasis. 2021;19(11):2791-800.

22.   Palmer J, Bozas G, Stephens A, Johnson M, Avery G, O'Toole L, et al. Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients. BMC Health Services Research. 2013;13(1):235.

23.   Peacock WF, Singer AJ. Reducing the hospital burden associated with the treatment of pulmonary embolism. Journal of Thrombosis and Haemostasis. 2019;17(5):720-36.

24.   Farmakis IT, Barco S, Mavromanoli AC, Konstantinides SV, Valerio L. Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism: Insights From the Hokusai-VTE Cancer Study. JACC: CardioOncology. 2022;4(4):507-18.

Tables and figures

Table 1: Characteristics of the patients with unsuspected pulmonary embolism

	Validation cohort %(n)
Age	Median 69 (Range 36-91)
Gender	
Male	57.8 (163)
Female	42.2 (119)
Setting	
Radical/adjuvant	28 (79)
Metastatic/incurable	72 (203)
Diagnosis	
Colorectal cancer, early	4.3 (12)
Colorectal cancer, metastatic	17.7 (50)
Oesophagogastric cancer, early	7.1 (20)
Oesophagogastric cancer, metastatic	4.3 (12)
Breast cancer, metastatic	9.2 (26)
Pancreaticobiliary cancer, advance	5 (14)
NSCLC Metastatic/SCLC	10.3 (29)
Other	42.2 (119)
Treatment	
Cytotoxic chemotherapy	68.1 (192)
Biological therapy	14.5 (41)
Hormonal therapy	12.1 (34)
Immunotherapy	4.6 (13)
Risk Factors for VTE	
Recent (30d) hospitalisation	15.2 (43)
Recent (30d) surgery	3.9 (11)
Indwelling CVC	17.4 (49)
PS	
0	47.2 (133)
1/2	44.7 (126)
3/4	6 (17)
MD	2.1 (6)

Extent of UPE	
Bilateral	38.3 (100)
Largest vessel: pulmonary artery (main, right, left)	16 (45)
Largest vessel: lobar branch(es)	20.3 (57)
Largest vessel: segmental	49 (138)
Largest vessel: sub-segmental	14.9 (42)
Symptoms (self-reported)	
Any new symptom	25.2 (71)
Worsening pre-existing symptoms	16.3 (46)
PESI group	
I/II	8.9 (25)
III	33.3 (94)
IV	41.8 (118)
V	15.6 (44)
MD	0.4 (1)

Table 2: Prognostic risk group (HULL Score CPR category) for mortality

Validation cohort	Proximate mortality					
	30 days		**90 days**		**180 days**	
HULL Score CPR category	Overall P = 0.066		Overall P <0.001		Overall P <0.001	
	Hazard ratios (95% CI)	**p**	**Hazard ratios (95% CI)**	**p**	**Hazard ratios (95% CI)**	**p**
Low-risk (HS 0)	1		1		1	
Intermediate-risk (HS 1-2)	1.05 (0.07, 16.1)	0.973	15.7 (2.1, 119.8)	0.008	10.5 (3.7, 29.7)	<0.001
High-risk (HS 3-4)	6.3 (0.7, 54.1)	0.092	39.5 (5.4, 290.9)	<0.001	17.6 (6.3, 49.2)	<0.001

Figure 1:

a. Kaplan Meier survival curves for the HULL Score CPR groups for the first 12 months of follow-up for derivation (i) and validation cohort (ii). Line separators for the 30-day, 90-day, and 180-day cut-offs and the median for survival are included. (Low risk: 0 green, Intermediate risk: 1-2 purple, High risk: 3-4 red)

b. Mortality by HULL Score CPR in derivation (2010-2014) and validation (2015-2020) cohorts

**Figure 2:** ROC curve analysis on the prognostic performance of the HULL Score CPR

30-d mortality
AUC= 0.717 1 - Specificity

90-d mortality
AUC= 0.772 1 - Specificity

180-d mortality
AUC= 0.751 1 - Specificity

overall mortality
AUC= 0.749 1 - Specificity

Table 1: HULL score clinical prediction rule (CPR)

Predictor	Weight
New or worsening symptom	
Yes	1
No	0
ECOG PS 0	0
ECOG PS 1 - 2	2
ECOG PS 3 - 4	3

HULL Score	HULL CPR risk category
0	Low risk
1-2	Intermediate risk
3-4	High risk

ECOG PS – Eastern Cooperative Oncology Group Performance Status

Table 2: Characteristics of the patients with unsuspected pulmonary embolism

	Derivation cohort %(n)	Validation cohort %(n)
Age	Median 67 (Range 27-91)	Median 69 (Range 36-91)
Gender		
Male	59 (139)	57.8 (163)
Female	41 (95)	42.2 (119)
Setting		
Radical/adjuvant	20 (46)	28 (79)
Metastatic/incurable	80 (188)	72 (203)
Diagnosis		
Colorectal cancer, early	5 (12)	4.3 (12)
Colorectal cancer, metastatic	20 (46)	17.7 (50)
Oesophagogastric cancer, early	7 (17)	7.1 (20)
Oesophagogastric cancer, metastatic	9 (21)	4.3 (12)
Breast cancer, metastatic	9 (21)	9.2 (26)
Pancreaticobiliary cancer, advance	9 (21)	5 (14)
NSCLC Metastatic/SCLC	12 (28)	10.3 (29)
Other	29 (68)	42.2 (119)
Treatment		
Cytotoxic chemotherapy	66 (154)	68.1 (192)
Biological therapy	13 (30)	14.5 (41)
Hormonal therapy	4 (10)	12.1 (34)
Immunotherapy	1 (2)	4.6 (13)
Risk Factors for VTE		
Recent (30d) hospitalisation	15 (36)	15.2 (43)
Recent (30d) surgery	2 (5)	3.9 (11)
Indwelling CVC	15 (35)	17.4 (49)
PS		
0	45 (105)	47.2 (133)
1/2	43 (100)	44.7 (126)
3/4	10 (23)	6 (17)
MD	3 (6)	2.1 (6)

Extent of UPE		
Bilateral	39 (91)	38.3 (100)
Largest vessel: pulmonary artery (main, right, left)	20 (46)	16 (45)
Largest vessel: lobar branch(es)	27 (63)	20.3 (57)
Largest vessel: segmental	42 (99)	49 (138)
Largest vessel: sub-segmental	11 (25)	14.9 (42)
Symptoms (self-reported)		
Any new symptom	42 (98)	25.2 (71)
Worsening pre-existing symptoms	21 (49)	16.3 (46)
PESI group		
I/II	13 (29)	8.9 (25)
III	42 (99)	33.3 (94)
IV	37 (86)	41.8 (118)
V	8 (20)	15.6 (44)
MD		0.4 (1)